Gelatin Capsule Shell Cross-Linking - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gelatin Capsule Shell Cross-Linking
The authors develop a pratical approach to avoid unwanted interactions between pepsin and SLS in dissolution Tier II tests.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 62-68

Hard gelatin capsules are a common solid oral dosage form, but exposure to accelerated conditions, e.g. 40 C and 75% relative humidity (RH), can cause capsule shell cross-linking. Capsule shell cross-linking arises from gelatin polymerization, a process facilitated by high temperature, high humidity, ultraviolet (UV) and visible irradiation, dyes, and aldehydes (1–4). The main impact of gelatin cross-linking is prolonged capsule disintegration time, and a subsequent slow-down of drug product dissolution rate. In the event that hindered dissolution arises from gelatin cross-linking and the product fails specification, USP <711> recommends the addition of enzymes (e.g., pepsin) to the dissolution medium to serve as the Tier II dissolution test (5). It is important, though, to confirm that dissolution failure is a direct outcome of cross-linked gelatin shells rather than degradation of drug product performance.

Sodium lauryl sulfate (SLS) is a surfactant commonly used in dissolution medium to improve the solubility of poorly water-soluble drugs. The presence of SLS in dissolution medium deactivates pepsin, which complicates the Tier II method described above (6). One option would be to redevelop the dissolution method and abandon SLS. But this option could be costly in time and resources, and may discourage the use of SLS in capsule formulations in general, despite its excellent solubilizing capability, low cost and ease of use. Performing Tier II dissolution tests in the presence of SLS is considered beneficial to the development and quality control of capsule formulations.

This article will detail the experimental procedures and the study results of a case where the above issues were encountered and tackled in the development of a capsule formulation. A slowdown in dissolution rate was discovered for the gelatin capsule formulation when it was stored at accelerated conditions of 40 C and 75% RH for three months.

Materials

Size one opaque hard gelatin capsule shells were purchased from Capsugel. Dissolution was performed using USP Apparatus II (paddles), Model VK 7000 (Varian). Stand-alone UV–Vis spectrometer with diode array capacity, Model 8453, was from Agilent. Capsule sinkers (size 8/23) were from Sotax. SLS (reagent grade > 99%) was purchased from Fisher Scientific. Full flow cannula filters (10 m) were from Quality Lab Accessories. Pepsin (800–2,500 units/mg) purified from porcine gastric mucosa was purchased from Sigma-Aldrich. All other chemicals were ACS grade or equivalent.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here